The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.
A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...
GP leaders have warned that the rollout of the weight loss drug tirzepatide (Mounjaro, Eli Lilly) will still have ...
Weight loss jab tirzepatide – commonly sold under the brand name Mounjaro – is set to become available via the NHS for ...
Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...
They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...
Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and acceptably safe for the treatment of type 2 diabetes and obesity, leading to ...
US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...
Losing weight can be a challenge for many. With so many variables present in everyday life, including stress, lack of sleep, ...
NICE has accepted a request from NHS England to slow down the roll out of weight-loss drug tirzepatide but GP workload ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback